CALL/AMGEN/500/0.1/20.09.24 | Market Closed - BOERSE MUENCHEN 14:27:01 2024-06-28 EDT | ||
| 0.023 EUR | +21.05% |
|
| Current month | +21.05% | ||
| 1 month | +9.52% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 0.023 | +21.05% |
| 24-06-27 | 0.019 | -5.00% |
| 24-06-26 | 0.02 | -28.57% |
| 24-06-25 | 0.028 | +27.27% |
| 24-06-24 | 0.022 | -15.38% |
Real-time BOERSE MUENCHEN
Last update June 28, 2024 at 02:27 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Goldman Sachs |
| WKN | GG2YK9 |
| ISIN | DE000GG2YK96 |
| Date issued | 2024-01-30 |
| Strike | 500 $ |
| Maturity | 2024-09-20 (84 Days) |
| Parity | 10 : 1 |
| Emission price | 0.02 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.048 € |
|---|---|
| Lowest since issue | 0.007 € |
| Spread | 0.1 € |
| Spread % | 83.33% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
312.4
USD
Average target price
316.4
USD
Spread / Average Target
+1.28%
- Stock Market
- Warrants
- Warrant
